The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Didronel     disodium 1,1-bis(hydroxy-oxido...

Synonyms: Calcimux, Ostedron, Etidron, Xydifon, Didronel R, ...
This record was replaced with 3305.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Etidronic acid

 

High impact information on Etidronic acid

 

Chemical compound and disease context of Etidronic acid

 

Biological context of Etidronic acid

 

Anatomical context of Etidronic acid

 

Associations of Etidronic acid with other chemical compounds

 

Gene context of Etidronic acid

  • To further test this hypothesis in a chronic state, we studied nine stable hypoxemic (PaO2 = 64 +/- 2 mm Hg [+/- SEM]) patients with COPD over five weeks: two weeks at normal plasma Pi; and three weeks at elevated plasma Pi, induced by etidronate disodium (Didronel; 750 mg orally daily) [30].
  • Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva [31].
  • Next we determined whether antiresorptive agents (calcitonin 1 microU/gip/day or sodium etidronate given cyclically at 10 micrograms/g po for 3 consecutive days out of every week) could prevent bone loss [32].
  • Disodium etidronate, a bisphosphonate, produced a two-fold improvement in the rate of his speech and gait, but did not affect his spasticity, dystonia, or ataxia [33].
  • Administration of etidronate disodium increased (p less than 0.05) plasma level of Pi (4.4 +/- 0.2 to 5.8 +/- 0.1 mg/dl), RBC level of Pi (3.1 +/- 0.2 to 4.1 +/- 0.2 mg/dl), RBC level of 2,3-DPG (16.2 +/- 1.1 to 21.3 g+/- 1.3 mumol/g of Hb) and P50 (23.7 +/- 0.5 to 26.0 +/- 0.8 mm Hg) [30].
 

Analytical, diagnostic and therapeutic context of Etidronic acid

References

  1. Treatment of hypercalcemia with etidronate disodium. Zweig, J.I., Shafer, N. JAMA (1980) [Pubmed]
  2. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. Krane, S.M., Kantrowitz, F.G., Byrne, M., Pinnell, S.R., Singer, F.R. J. Clin. Invest. (1977) [Pubmed]
  3. Etidronate disodium in the treatment of Paget's disease of bone. Krane, S.M. Ann. Intern. Med. (1982) [Pubmed]
  4. Clinical and radiographic improvement of bone of the second lumbar vertebra in Paget's disease following therapy with etidronate disodium: a case report. Nicholas, J.J., Helfrich, D.J., Cooperstein, L., Goodman, M. Arthritis Rheum. (1989) [Pubmed]
  5. Alternate calcitonin and etidronate disodium therapy for Paget's bone disease. Perry, H.M., Droke, D.M., Avioli, L.V. Arch. Intern. Med. (1984) [Pubmed]
  6. Treatment of hyperparathyroidism with etidronate disodium. Licata, A.A., O'Hanlon, E. JAMA (1983) [Pubmed]
  7. Etidronate disodium in the management of malignancy-related hypercalcemia. Hasling, C., Charles, P., Mosekilde, L. Am. J. Med. (1987) [Pubmed]
  8. Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium. Jacobs, T.P., Gordon, A.C., Silverberg, S.J., Shane, E., Reich, L., Clemens, T.L., Gundberg, C.M. Am. J. Med. (1987) [Pubmed]
  9. Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. Altman, R.D. Am. J. Med. (1985) [Pubmed]
  10. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. Gucalp, R., Ritch, P., Wiernik, P.H., Sarma, P.R., Keller, A., Richman, S.P., Tauer, K., Neidhart, J., Mallette, L.E., Siegel, R. J. Clin. Oncol. (1992) [Pubmed]
  11. Acute intravenous infusion of disodium dihydrogen (1-hydroxyethylidene)diphosphonate: mechanism of toxicity. Francis, M.D., Slough, C.L. Journal of pharmaceutical sciences. (1984) [Pubmed]
  12. Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy. Zucchelli, P., Catizone, L., Casanova, S., Fabbri, L., Fusaroli, M. Mineral and electrolyte metabolism. (1982) [Pubmed]
  13. Parenteral diphosphonates for treating malignant hypercalcemia. Jung, A., van Ouwenaller, C., Chantraine, A., Courvoisier, B. Cancer (1981) [Pubmed]
  14. Appearance of a gastric ulcer during diphosphonate therapy in a woman with CRST syndrome. Saunders, R.L. South. Med. J. (1977) [Pubmed]
  15. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. Orme, S.M., Simpson, M., Stewart, S.P., Oldroyd, B., Westmacott, C.F., Smith, M.A., Belchetz, P.E. Clin. Endocrinol. (Oxf) (1994) [Pubmed]
  16. Effect of etidronate disodium on bone turnover following surgical menopause. Smith, M.L., Fogelman, I., Hart, D.M., Scott, E., Bevan, J., Leggate, I. Calcif. Tissue Int. (1989) [Pubmed]
  17. Heterotopic ossification heralded by a knee effusion. Baron, M., Stern, J., Lander, P. J. Rheumatol. (1983) [Pubmed]
  18. Heterotopic ossification and peripheral nerve entrapment: early diagnosis and excision. Brooke, M.M., Heard, D.L., de Lateur, B.J., Moeller, D.A., Alquist, A.D. Archives of physical medicine and rehabilitation. (1991) [Pubmed]
  19. Evaluation of sodium etidronate in the treatment of Paget's disease of bone. Osteitis deformans. Stein, I., Shapiro, B., Ostrum, B., Beller, M.L. Clin. Orthop. Relat. Res. (1977) [Pubmed]
  20. Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3. Shevrin, D.H., Gorny, K.I., Rosol, T.J., Kukreja, S.C. Prostate (1991) [Pubmed]
  21. Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal-cord injury patients. Stover, S.L., Niemann, K.M., Miller, J.M. The Journal of bone and joint surgery. American volume. (1976) [Pubmed]
  22. Effect of etidronate disodium on filterability of sickle cell erythrocytes. Van Duzee, B.F., Sunberg, R.J., Benedict, J.J. Journal of pharmaceutical sciences. (1980) [Pubmed]
  23. Metabolic effects of diphosphonate in primary hyperparathyroidism. Kaplan, R.A., Geho, W.B., Poindexter, C., Haussler, M., Dietz, G.W., Pak, C.Y. Journal of clinical pharmacology. (1977) [Pubmed]
  24. Effects of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on interleukin 1 production by macrophages. Aida, Y., Toda, Y., Shimakoshi, Y., Yamada, K., Aono, M. Microbiol. Immunol. (1986) [Pubmed]
  25. Calcium absorption in diphosphonate-treated rats: effect of parathyroid function, dietary calcium and phosphorus. Bonjour, J.P., Fleisch, H., Trechsel, U. J. Physiol. (Lond.) (1977) [Pubmed]
  26. Photoluminescence properties of four-coordinate gold(I)-phosphine complexes of the types [Au(diphos)2]PF6 and [Au2(tetraphos)2](PF6)2. Delfs, C.D., Kitto, H.J., Stranger, R., Swiegers, G.F., Wild, S.B., Willis, A.C., Wilson, G.J. Inorganic chemistry. (2003) [Pubmed]
  27. Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report. Surrey, E.S., Fournet, N., Voigt, B., Judd, H.L. Obstetrics and gynecology. (1993) [Pubmed]
  28. Fibrodysplasia (myositis) ossificans progressiva treated with disodium etidronate. Hentzer, B., Jacobsen, H.H., Asboe-Hansen, G. Clinical radiology. (1978) [Pubmed]
  29. Effect of decreased O2 affinity of hemoglobin on work performance during exercise in healthy humans. Farber, M.O., Sullivan, T.Y., Fineberg, N., Carlone, S., Manfredi, F. J. Lab. Clin. Med. (1984) [Pubmed]
  30. Pharmacologic elevation of blood inorganic phosphate in hypoxemic patients with COPD. Palange, P., Carlone, S., Serra, P., Mannix, E.T., Manfredi, F., Farber, M.O. Chest (1991) [Pubmed]
  31. Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. Rogers, J.G., Dorst, J.P., Geho, W.B. J. Pediatr. (1977) [Pubmed]
  32. A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression. Kung, A.W., Ng, F. Thyroid (1994) [Pubmed]
  33. Functional improvement in a patient with cerebral calcinosis using a bisphosphonate. Loeb, J.A. Mov. Disord. (1998) [Pubmed]
  34. Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. Singer, F., Siris, E., Shane, E., Dempster, D., Lindsay, R., Parisien, M. J. Bone Miner. Res. (1994) [Pubmed]
  35. Therapy of hypercalcemia of malignancy. Singer, F.R., Fernandez, M. Am. J. Med. (1987) [Pubmed]
  36. Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Van Cleemput, J., Daenen, W., Geusens, P., Dequeker, P., Van De Werf, F., VanHaecke, J. Transplantation (1996) [Pubmed]
  37. Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients. Ringenberg, Q.S., Ritch, P.S. Clinical therapeutics. (1987) [Pubmed]
 
WikiGenes - Universities